BACKGROUND: Information on the potential costs of HIV/AIDS to the private sector is needed if companies are to be given a financial incentive to invest in prevention and treatment interventions. OBJECTIVES: To estimate the cost of HIV/AIDS to businesses in southern Africa using company-specific data on employees, costs, and HIV prevalence. METHODS: : Six formal sector enterprises in South Africa and Botswana provided detailed human resource, financial, and medical data and carried out voluntary, anonymous HIV seroprevalence surveys. The present value of incident HIV infections with a 9-year median survival and 7% real discount rate was estimated. Costs included were sick leave; productivity loss; supervisory time; retirement, death, disability, and medical benefits; and recruitment and training of replacement workers. RESULTS: HIV prevalence in the workforces studied ranged from 7.9 to 25.0%. HIV/AIDS among employees added 0.4-5.9% to the companies' annual salary and wage bills. The present value of an incident HIV infection ranged from 0.5 to 3.6 times the annual salary of the affected worker. Costs varied widely across firms and among job levels within firms. Key reasons for the differences included HIV prevalence, levels and stability of employee benefits, and the contractual status of unskilled workers. Some costs were omitted from the analysis because of lack of data, and results should be regarded as quite conservative. CONCLUSIONS: AIDS is causing labor costs for businesses in southern Africa to rise and threatens the competitiveness of African industry. Research on the effectiveness of workplace interventions is urgently needed.
BACKGROUND: Information on the potential costs of HIV/AIDS to the private sector is needed if companies are to be given a financial incentive to invest in prevention and treatment interventions. OBJECTIVES: To estimate the cost of HIV/AIDS to businesses in southern Africa using company-specific data on employees, costs, and HIV prevalence. METHODS: : Six formal sector enterprises in South Africa and Botswana provided detailed human resource, financial, and medical data and carried out voluntary, anonymous HIV seroprevalence surveys. The present value of incident HIV infections with a 9-year median survival and 7% real discount rate was estimated. Costs included were sick leave; productivity loss; supervisory time; retirement, death, disability, and medical benefits; and recruitment and training of replacement workers. RESULTS:HIV prevalence in the workforces studied ranged from 7.9 to 25.0%. HIV/AIDS among employees added 0.4-5.9% to the companies' annual salary and wage bills. The present value of an incident HIV infection ranged from 0.5 to 3.6 times the annual salary of the affected worker. Costs varied widely across firms and among job levels within firms. Key reasons for the differences included HIV prevalence, levels and stability of employee benefits, and the contractual status of unskilled workers. Some costs were omitted from the analysis because of lack of data, and results should be regarded as quite conservative. CONCLUSIONS:AIDS is causing labor costs for businesses in southern Africa to rise and threatens the competitiveness of African industry. Research on the effectiveness of workplace interventions is urgently needed.
Authors: Bruce A Larson; Mathew P Fox; Sydney Rosen; Margret Bii; Carolyne Sigei; Douglas Shaffer; Fredrick Sawe; Kelly McCoy; Monique Wasunna; Jonathan L Simon Journal: BMC Public Health Date: 2009-07-15 Impact factor: 3.295
Authors: Ighovwerha Ofotokun; Jose Nilo G Binongo; Eli S Rosenberg; Michael Kane; Rick Ifland; Jeffrey L Lennox; Kirk A Easley Journal: BMC Int Health Hum Rights Date: 2010-02-02
Authors: Leonor Guariguata; Ingrid de Beer; Rina Hough; Els Bindels; Delia Weimers-Maasdorp; Frank G Feeley; Tobias F Rinke de Wit Journal: BMC Public Health Date: 2012-01-18 Impact factor: 3.295
Authors: Leonor Guariguata; Ingrid de Beer; Rina Hough; Pancho Mulongeni; Frank G Feeley; Tobias F Rinke de Wit Journal: PLoS One Date: 2015-07-13 Impact factor: 3.240
Authors: Rory Leisegang; Susan Cleary; Michael Hislop; Alistair Davidse; Leon Regensberg; Francesca Little; Gary Maartens Journal: PLoS Med Date: 2009-12-01 Impact factor: 11.069
Authors: Gesine Meyer-Rath; Jan Pienaar; Brian Brink; Andrew van Zyl; Debbie Muirhead; Alison Grant; Gavin Churchyard; Charlotte Watts; Peter Vickerman Journal: PLoS Med Date: 2015-09-01 Impact factor: 11.069